Background-Most guidelines for treatment of hypertension recommend a blood pressure (BP) goal of Ͻ140/ 90 mm Hg, and a more aggressive goal of Ͻ130/80 mm Hg for patients with diabetes mellitus. However, in the recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, a lower BP was not beneficial. The optimal BP target in subjects with diabetes mellitus or those with impaired fasting glucose/glucose tolerance is therefore not well defined. Methods and Results-We performed PUBMED, EMBASE, and CENTRAL searches for randomized clinical trials from 1965 through October 2010 of antihypertensive therapy in patients with type 2 diabetes mellitus or impaired fasting glucose/impaired glucose tolerance that enrolled at least 100 patients with achieved systolic BP of Յ135 mm Hg in the intensive BP control group and Յ140 mm Hg in the standard BP control group, had a follow-up of at least 1 year, and evaluated macrovascular or microvascular events. We identified 13 randomized clinical trials enrolling 37 736 participants. Intensive BP control was associated with a 10% reduction in all-cause mortality (odds ratio, 0.90; 95% confidence interval, 0.83 to 0.98), a 17% reduction in stroke, and a 20% increase in serious adverse effects, but with similar outcomes for other macrovascular and microvascular (cardiac, renal, and retinal) events compared with standard BP control. The results were similar in a sensitivity analysis using a bayesian random-effects model. More intensive BP control (Յ130 mm Hg) was associated with a greater reduction in stroke, but did not reduce other events. Meta-regression analysis showed continued risk reduction for stroke to a systolic BP of Ͻ120 mm Hg. However, at levels Ͻ130 mm Hg, there was a 40% increase in serious adverse events with no benefit for other outcomes. Conclusions-The present body of evidence suggests that in patients with type 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a systolic BP treatment goal of 130 to 135 mm Hg is acceptable. However, with more aggressive goals (Ͻ130 mm Hg), we observed target organ heterogeneity in that the risk of stroke continued to fall, but there was no benefit regarding the risk of other macrovascular or microvascular (cardiac, renal and retinal) events, and the risk of serious adverse events even increased. (Circulation. 2011;123:2799-2810.)
BP therapy did not reduce the rate of a composite cardiovascular events. However, intensive therapy reduced the risk of stroke. 5 The systolic BP achieved at the end of 1 year in ACCORD was 133.5 mm Hg in the standard therapy group and 119 mm Hg in the intensive therapy group. This finding begs the question of whether the BP goal should be Ͻ140 mm Hg, which is the standard for all non-high-risk hypertensives, Ͻ130 mm Hg on the basis of most national and international guidelines, or Ͻ120 mm Hg on the basis of the significant stroke reduction seen in the intensive arm of the ACCORD-BP trial.
Our objective was to evaluate target BP goals for subjects with type 2 diabetes mellitus. Given that subjects with impaired fasting glucose (IFG) or glucose intolerance (IGT) are a spectrum in the continuum of insulin resistance and diabetes mellitus, we also evaluated these subsets.
Methods

Eligibility Criteria
We conducted PUBMED, EMBASE, and CENTRAL searches using the terms "diabetes" and "diabetes mellitus" in humans from 1965 until October 2010 with the limit "randomized controlled trials." We checked the reference lists of review articles, meta-analyses, and original studies identified by the electronic searches to find other eligible trials. There was no language restriction for the search. Authors of publications were contacted when results were unclear or when relevant data were not reported.
Eligible trials had to fulfill the following criteria to be included in this analysis: (1) randomized clinical trials of participants with type 2 diabetes mellitus/IFG/IGT (2) reporting Ն1-year outcomes (3) and enrolling at least 100 patients (4) who achieved systolic BP Յ140 mm Hg in both arms. Additionally, because the objective of the present study was to test outcomes based on BP targets, the following criteria were required: (1) achieved systolic BP in the intensive BP group of Յ135 mm Hg, (2) achieved systolic BP in the standard BP group of Յ140 mm Hg, and (3) had a systolic BP difference between the intensive and standard BP group of at least 3 mm Hg. We chose this cut point because this difference in systolic BP between treatment arms was the minimum required to show a reduction in cardiovascular events. 6 Studies in which there was no significant difference in BP between arms (Ͻ3 mm Hg) were excluded. For example, if studies evaluated 2 antihypertensive agents, but uptitrated or added medication to ensure no difference in final systolic BPs, they were excluded, because such studies are not expected to provide information on BP targets.
Selection and Quality Assessment
Two authors (S.B. and S.K.) independently assessed trial eligibility and trial bias risk and extracted data. The bias risk of trials was assessed by the use of the components recommended by the Cochrane Collaboration 7 : (1) sequence generation of allocation; (2) allocation concealment; (3) blinding of participants, personnel, and outcome assessors; (4) incomplete outcome data; (5) selective outcome reporting; and (6) other sources of bias. Of note, the studies did not differ for quality components 4 through 6. Trials with high or unclear risk for bias for any 1 of the first 3 components were considered trials with a high risk of bias. Otherwise, they were considered trials with low risk of bias.
Data Extraction and Synthesis
For the purpose of this analysis, the intensive BP group was defined as the group in which the final achieved systolic BP was Յ135 mm Hg, and the standard BP group as the group in which the final achieved systolic BP was Յ140 mm Hg. Of note, these terms are based on mean achieved systolic BP, are used for descriptive purposes for this article, and are not necessarily the strategy used in the trial (ie, not all trials tested a BP strategy).
Long-term macrovascular and microvascular complications were evaluated. The macrovascular outcomes were all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, heart failure, angina pectoris, and revascularization. The microvascular outcomes evaluated were development of microalbuminuria, overt nephropathy, end-stage renal disease/dialysis, doubling of serum creatinine, neuropathy, and retinopathy. We also evaluated the serious adverse effects (SAEs) as reported between the 2 groups. The SAEs were variously defined as events that are life-threatening, cause permanent disability, or necessitate hospitalization or withdrawal owing to adverse effects.
Statistical Analysis
An intention-to-treat traditional meta-analysis was performed in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 7,8 with the use of standard software (Stata 9.0, Stata Corp, College Station, TX). 9 Heterogeneity was assessed with the I 2 statistic, 10 with I 2 Ͻ25% considered low and I 2 Ͼ75% considered high. We used the Peto method for odds ratio (OR), 11, 12 which is viewed as the most optimal approach when there are relatively few events in individual trials. Publication bias was estimated visually by funnel plots and by use of the Begg and Egger test. 13 Analyses were performed after the studies were further stratified on the basis of the achieved systolic BP in the intensive group: Ͼ130 but Յ135 mm Hg (less intensive group) versus Յ130 mm Hg (more intensive group).
A meta-regression analysis was performed to explore the relationship between systolic BP and outcomes. For this purposes, the mean achieved systolic BP was used as a continuous variable. We used residual maximum likelihood to estimate the additive (betweenstudy) component of variance 2 for the meta-regression analysis. Bootstrap analyses were performed with a Monte Carlo permutation test for meta-regression using 10 000 random permutations. 14
Sensitivity Analyses
In a meta-analysis of clinical trials with binary outcomes such as those described above, a normal approximation for the summary treatment effect measure in each trial may not be appropriate when some of the trials in the meta-analysis are small or the observed risks are close to 0 or 1. To avoid this, the binomial distribution within trials can be used directly as described by Warn et al. 15 The advantages of bayesian methods include a modeling framework that overcomes issues such as the appropriate treatment of small trials and the ability to consider distributions other than normal for the random effects. 15 Of note, the Peto OR methodology used above more closely approximates a fixed-effect model; hence, in situations in which the results of the bayesian model differed from those of the traditional model, the bayesian model was used for inference (given that it is a random-effects model). The BUGS code for implementing the model is as described by Warn et al. 15 Minimally informative prior distributions were used for log ORs and for random-effects standard deviation comparisons of treatments, so the findings are close to those obtained with frequentist methods. All bayesian analyses were conducted with WinBUGS 1.4.3.
Subgroup Analyses
Sensitivity analyses were performed for the following subgroups: trials with low to trials with high risk of bias; trials that tested a BP strategy versus others; and including and excluding trials that enrolled patients with IFG/IGT. We estimated the difference between the estimates of the subgroups according to tests for interaction. 16 We considered values of PϽ0.10 to indicate that the effects of treatment differed between the tested subgroups.
Results
Study Selection
We identified 1330 randomized, controlled trials through electronic and hand searches, of which a total of 13 random-ized, controlled trials 5,17-29 fulfilled the inclusion criteria and were chosen for this analysis (Figure 1 ). The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) included was the report on the subset of patients with new glucose disorder. 18 We included the ACCORD-Eye substudy 22 for the retinopathy outcome analysis. Of note, 6 trials were excluded for violation of 1 or 2 BP inclusion criteria, and most of them would have been excluded for violation of other criteria as well ( Table I in the online-only Data Supplement). 30 -35 Only 3 of the 6 trials were excluded, because the difference in BP achieved was Ͻ3 mm Hg. Among these, the trial by Ahmad et al 33 had no differences in BP, whereas the other 2 trials 34,35 had a difference of 1 mm Hg between the 2 arms. The later trials would have been excluded anyway because the mean follow-up was Ͻ1 year.
Characteristics of the Trials
The baseline characteristics and bias-risk assessment are summarized in Tables 1 and 2 and Table II in the online-only Data Supplement. The 13 randomized, controlled trials enrolled 37 736 participants, 19 042 (50.5%) in the intensive BP control group and 18 694 (49.5%) in the standard BP control group, and were followed up for 4.8Ϯ1.3 years (weighted mean). Of the 13 trials, only 5 tested a BP strategy (intensive versus standard) by design. 5, 24, 26, 29, 36 The Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) trial and the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trials enrolled patients with IFG. Of note, the BP achieved in the standard group of Fogari et al 25 was 140.4 mm Hg, which was close to the threshold of Յ140 mm Hg; hence, it has been included in this analysis. In addition, in the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, the BP in the intensive group for most of follow-up was 134 to 135 mm Hg.
Quality Assessments
Among the 13 randomized, controlled trials considered for this analysis, 9 were considered trials with low risk of bias as described in the Methods section. The rest were considered to have an unclear or a high risk of bias (Table 2 ).
Macrovascular Outcomes
Intensive BP control group was associated with a 10% reduction in all-cause mortality compared with standard BP control, driven largely by the trials with achieved systolic BP Ͼ130 but Յ135 mm Hg (less intensive group; Figure 2A ). The test for interaction was significant (Pϭ0.09), so that the point estimate was directionally opposite for systolic BP Յ130 mm Hg compared with the group with achieved systolic BP Ͼ130 but Յ135 mm Hg (Figure 2A ). There was no heterogeneity (I 2 ϭ0.0%), and bias was insignificant ( Figure I in the online-only Data Supplement).
For the outcomes of cardiovascular mortality ( Figure 2B ), myocardial infarction ( Figure 3A) , and heart failure ( Figure  3B ), there was no difference between the 2 groups, but the point estimate favored the intensive group, driven largely by the trials with achieved systolic BP Ͼ130 but Յ135 mm Hg (less intensive group). The results were similar for the more intensive versus less intensive group comparison (P interaction Ͼ 0.10 for all comparisons; Figures 2B, 3A , and 3B). There was low to moderate heterogeneity (I 2 ϭ6.8%, 0.0%, and 47.8%, respectively), and bias was insignificant (Figures II through VI in the online-only Data Supplement).
For the outcome of stroke ( Figure 4A ), intensive BP control was associated with a 17% reduction in the odds compared with the standard control group, with a greater magnitude of benefit in trials in which the systolic BP was Յ130 mm Hg (P interaction ϭ0.005), in which there was a 47% decrease in the odds of stroke compared with the standard control group. There was no to low heterogeneity (I 2 ϭ27.0%), and bias was insignificant ( Figure V in the online-only Data Supplement).
There was no difference between the 2 groups in the outcomes of angina pectoris (OR, 1.07; 95% confidence interval [CI], 0.92 to 1.24) or revascularization (OR, 0.97; 95% CI, 0.85 to 1.12), with similar results for the more intensive versus less intensive group comparison (P interaction Ͼ0.10 for all comparisons).
The above results were similar in a sensitivity analysis using a bayesian random-effects model ( Table 3) with an 11% decreased odds of all-cause mortality and a 30% decreased odds of stroke with intensive BP control with no difference for other outcomes.
Serious Adverse Events
In the few studies that reported SAEs, intensive control group was associated with a 20% increase in SAEs (OR, 1.20; 95% CI, 1.08 to 1.32), which was greater in magnitude in studies with more intense control of BP (Յ130 mm Hg) in which there was a 40% increase in SAEs (OR, 1.40; 95% CI, 1.19 to 1.64; P interaction ϭ0.01). There was significant heterogeneity in this analysis (I 2 ϭ78.8%).
Microvascular Outcomes
For the outcome of new-onset microalbuminuria, intensive control was associated with a 17% reduction in the odds compared with the standard control group (OR, 0.83; 95% CI, 0.77 to 0.89). Similarly, for the outcome of overt nephropathy, intensive control was associated with a 27% reduction in the odds compared with the standard control group, with greater benefit with more intensive BP control (Յ130 mm Hg) in which there was a 36% reduction compared with standard control (P interaction ϭ0.06; Figure 5 ). However, there was moderate heterogeneity in this analysis (I 2 ϭ61.3%). Other measures of nephropathy such as end-stage renal disease/dialysis or doubling of serum creatinine were not different between the groups, and only a few studies reported these outcomes (data not shown). In addition, none of these outcomes was significantly different in a sensitivity analysis using a bayesian random-effects model ( Table 3) .
For the outcome of retinopathy, there was no difference between the 2 groups (OR, 0.93; 95% CI, 0.83 to 1.05) with low heterogeneity (I 2 ϭ21.5%) and similar results across the more intensive versus less intensive comparison (P interaction ϭ 0.36). In the 3 studies that reported the risk of neuropathy, there was no difference between the 2 groups (OR, 1.26; 95% CI, 0.98 to 1.62) with moderate heterogeneity (I 2 ϭ26.9%), with similar results across the more intensive versus less intensive comparison (P interaction ϭ0.16).
The results were similar in a sensitivity analysis using a bayesian random-effects model ( Table 3) .
Meta-Regression Analysis
The relationships between final achieved systolic BP (in the intensive control group) and the risk of macrovascular and microvascular outcomes are shown in Figure 6A through 6F. Results based on a sensitivity analysis using a bayesian random-effects model and evaluating the relationship between final achieved systolic BP and outcomes are outlined in Table 3 .
For most of the macrovascular and microvascular outcomes (other than stroke), lower was not better (Figure 6A  through 6F ). For the outcome of stroke, lower was better, with benefit even down to a systolic BP of Ͻ120 mm Hg ( Figure 6D ). The residual maximum likelihood estimate of between-study variance ( 2 ) used was 0, and the percent residual variation resulting from heterogeneity was 0.0%. OR indicates odds ratio; Cr I, credibility interval; 2 , between-study variance; SBP, systolic blood pressure; and CV, cardiovascular.
*Final achieved SBP in the intensive group. †Negative slope represents an inverse relationship (lower SBP associated with worse outcomes); positive slope, a direct relationship (lower SBP associated with better outcomes).
Using Monte Carlo permutation with 10 000 random permutations, we identified a value of Pϭ0.035 (SE, 0.0018) for the above analysis. For each 1-mm Hg-lower systolic BP, the odds of stroke reduced by 3% (95% CI, 1 to 7). The results were similar in a sensitivity analysis using a bayesian random-effects model ( Table 3 ).
Subgroup Analyses
Subgroup analyses did not make a noticeable difference in the above results (Table 4 ).
Discussion
The principal finding of the present study is that no single optimal systolic goal BP level can be identified in patients with type 2 diabetes mellitus/IFG/IGT. Intensive BP control (Յ135 mm Hg) was associated with a significant reduction in macrovascular (all-cause mortality and stroke) events but with an increase in SAEs compared with standard BP control (Յ140 mm Hg). Although lower was better for stroke (even Ͻ120 mm Hg for systolic BP), this was not true for other cardiac, renal, or retinal outcomes. Thus, below a systolic BP of 130 mm Hg, there seems to be target organ heterogeneity in that there is continued reduction of stroke but an increase in SAEs without any further benefit for other cardiovascular outcomes.
Type 2 Diabetes Mellitus and Blood Pressure
Patients with diabetes mellitus are at increased risk for cardiovascular outcomes, so that these patients are considered coronary artery disease risk equivalents. As such, major national and international guidelines recommend a more aggressive BP goal of Ͻ130/80 mm Hg in patients with diabetes mellitus. [1] [2] [3] [4] Intensive therapy is not without drawbacks. In the ACCORD BP trial, the risk of serious adverse events was 2.6 times higher in the intensive group compared with the standard therapy group, with a 17-fold increase in hypotension and a 10-fold increase in hyperkalemia. However, the absolute rates of above adverse events were rather low. Moreover, in patients with coronary artery disease, a J-shaped curve relationship has been documented with BP (particularly diastolic) and cardiovascular events so that lower pressures are associated with increased risk of events. 37 Regardless of the J-curve hypothesis, the principle of primum nonnocere mandates that we show evidence of benefit for intensive BP control before such a treatment strategy is advocated.
The result of the present study shows that the relationship between systolic BP and target organ risk reduction is complex. For macrovascular outcomes, intensive BP control (Յ135 mm Hg) was associated with a reduction in death and stroke. Although there was a direct linear relationship between systolic BP and stroke, so that lower was indeed better, the same was not true for death and other cardiac events. For cardiac events, further reduction below 130 mm Hg was not beneficial, with the point estimate of the OR directionally opposite that seen for the less intensive BP group (Ͼ130 and Յ135 mm Hg) for death. Of note, in ACCORD there was no difference in all-cause mortality (1.28%/y versus 1.19%/y; Pϭ0.55) or cardiovascular mortality (0.52%/y versus 0.49%/y; Pϭ0.74) with intensive therapy compared with standard therapy. This begs the question of whether there is a relatively flat part of the curve where there is neither benefit nor excess harm of a cardiac event. In analyses of both the Treating to New Targets (TNT) trial 38 and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT TIMI 22) trial, 39 we have shown a J-shaped relationship between BP and cardiovascular events. However, for systolic BPs between 110 and 140 mm Hg, the risk was relatively flat, and excess risk was seen at systolic BPs Ͻ110 mm Hg. However, once systolic BP is lowered to Ͻ130 mm Hg, there may be target organ heterogeneity, and clinicians will have to be cognizant of the increased risk of SAEs and possibly cardiac events. Our results are concordant with the analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration. 40 Traditional teaching implies that good BP control will reduce macrovascular events, whereas good diabetes control 
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is necessary for a reduction in microvascular events. In our analysis, although certain renal events benefitted from intensive BP control, the results were not consistently seen in the bayesian random-effects model. Given the moderate to significant heterogeneity in most of the analysis for microvascular outcomes, the random-effects model is likely to be more robust, suggesting no benefit of intensive BP control on any of the microvascular outcomes.
Study Limitations
All of the trials did not report all of the outcomes. The subgroup analyses might suffer from multiple testing and are best described as secondary and hypothesis generating only.
In this analysis, we tested a BP goal of Յ140 mm Hg with that of Յ135 mm Hg and not, say, Յ130 mm Hg for several reasons: (1) We aimed to ensure that we use data from as many relevant studies as possible because the number of studies was limited if the criterion was tightened to 130 mm Hg; (2) we aimed to test whether evidence exists for even a 135-mm Hg goal; and finally, and more importantly, (3) the cut points are less relevant because, in our regression analysis, the mean achieved BP was treated as a continuous variable and our conclusions and recommendations are based on this. Moreover, the intensive group was substratified into a more intensive group (Յ130 mm Hg) versus less intensive group (Ͼ130 but Յ135 mm Hg). In addition, in some of the trials, the mean systolic BP achieved in the standard group was more than the systolic BP achieved in the intensive group of other trials. However, the regression analysis using systolic BP as continuous variable accounts for this; hence, the BP targets are derived from this. In trials not testing a BP strategy, the most commonly used antihypertensive agent was an angiotensin-converting enzyme inhibitor, and the possibility that the beneficial effects on certain outcomes are due to this medication alone rather than a BP effect cannot be ruled out. In addition, our analysis is based on achieved BP, and many factors, including survivorship, will affect the end-ofstudy achieved BP. The definition of SAEs varied, and the trials did not consistently report the components to perform any additional analyses.
Conclusions
The present body of evidence suggests that intensive BP control (Յ135 mm Hg) reduces the risk of macrovascular (death, stroke) events in patients with type 2 diabetes mellitus/IFG/IGT. A treatment goal of 130 to 135 mm Hg, similar to the achieved BP of 133.5 mm Hg in the standard therapy group of the ACCORD trial, is therefore acceptable, and more aggressive goals to 120 mm Hg can be considered in patients at higher risk of stroke. However, at a systolic BP Ͻ130 mm Hg, there may be target organ heterogeneity, and these cerebrovascular benefits have to be balanced against an increased risk of SAEs and a lack of benefit for cardiac, renal, and retinal outcomes.
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